Limaprost

ApprovedSmall molecule

SSeoul National University Hospital

Limaprost is one of 13 small molecule programs targeting Lumbar Spinal Stenosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lumbar Spinal StenosisActive, not recruiting

MyelopathyActive, not recruiting

Lumbar Spinal StenosisApproved

Active, not recruiting

MyelopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Myelopathy

#DrugCompanyPhaseTrials

Immunoglobulin

Sanofi

Approved

1 2

Prialt

TTerezinha de Jesus Esteves Barata

Approved

1 3

Rilutek

AAzurity Pharmaceuticals

Phase 3

1 4

Rituxan

Roche

Phase 2

1 5

Ibudilast

UUniversity of California, Los Angeles

Phase 3

1 6

Limaprost

SSeoul National University Hospital

Approved

1 7

KW-0761

Kyowa Kirin Co., Ltd.

Phase 3

1 8

Methionine

SSt. Jude Children's Research Hospital

Phase 3

1 9

Zidovudine/lamivudine

Gilead

Phase 3

1 10

NK Cells

SSouthwest Hospital, China

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelopathy1 trial

The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

Completed·SSeoul National University Hospital·Phase 3·NCT02125981·160 enrolled

Lumbar Spinal Stenosis1 trial

A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis

Completed·YYungjin Pharm. Co., Ltd.·Phase 4·NCT01888536·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Limaprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Limaprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Limaprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSeoul National University Hospital

Limaprost

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelopathy1 trial

Lumbar Spinal Stenosis1 trial

References

Drug Info

Quick Facts

Related News